Chester County News and Community Website
BERWYN, PA — AscellaHealth has announced significant enhancements to its service model and infrastructure to support specialty and rare disease drug manufacturers facing heightened market disruption. As pressures mount from sudden …
AscellaHealth Expands Services to Help Drugmakers Navigate Market Volatility Read More
HARRISBURG, PA — The Pennsylvania Department of Community and Economic Development (DCED) has announced a $2 million investment in Neovate Life Sciences GP I, LLC (Neovate), a venture capital firm …
Pennsylvania Invests $2 Million to Boost Life Sciences Innovation Read More BERWYN, PA — AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide stakeholders with comprehensive insights into current and upcoming specialty and rare …
AscellaHealth Launches Specialty & Rare Pipeline Digest to Guide Pharmaceutical Stakeholders Read More BERWYN, PA — AscellaHealth has unveiled its Specialty & Rare Pipeline Digest™, a comprehensive digital resource aimed at providing critical information on specialty and rare disease drug launches, biosimilars, and cell …
AscellaHealth Introduces Specialty & Rare Pipeline Digest to Advance Healthcare Insights Read More BERWYN, PA — AscellaHealth has unveiled its latest edition of the Specialty & Rare Pipeline Digest™, a vital digital resource that tracks developments in specialty and rare disease medications, including …
AscellaHealth Highlights Market Trends with Specialty & Rare Pipeline Digest Read More BERWYN, PA — AscellaHealth has unveiled its latest Specialty & Rare Pipeline Digest™ for the second quarter of 2024. This quarterly publication is known for its extensive coverage of new, …
AscellaHealth Releases Quarterly Specialty & Rare Pipeline Digest Read More BERWYN, PA — AscellaHealth has released its latest edition of the Specialty & Rare Pipeline Digest™. This quarterly digital publication stands as the industry’s most detailed resource on imminent specialty …
AscellaHealth Unveils Quarter’s Insights on Specialty and Rare Disease Drug Developments Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently announced financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on …
FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial Read More